08:30 AM EST, 11/27/2024 (MT Newswires) -- Novo Nordisk ( NVO ) and KKR's (KKR) joint acquisition of Sylvan International Biotechnology in China was cleared by the EU's antitrust review, the European Commission said Wednesday.
The Commission said it found that the proposed transaction would not raise competition concerns as the joint venture would have "negligible activities" in the European Economic Zone.